Axa S.A. Sells 18,618 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

AXA S.A. lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 772,391 shares of the medical equipment provider's stock after selling 18,618 shares during the period. Intuitive Surgical comprises approximately 1.2% of AXA S.A.'s holdings, making the stock its 10th largest holding. AXA S.A. owned about 0.22% of Intuitive Surgical worth $403,157,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ISRG. Bennett Selby Investments LP lifted its stake in shares of Intuitive Surgical by 3.9% in the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider's stock valued at $234,000 after purchasing an additional 17 shares during the period. Onefund LLC raised its position in shares of Intuitive Surgical by 1.9% in the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after acquiring an additional 18 shares during the period. LVW Advisors LLC boosted its stake in shares of Intuitive Surgical by 1.3% during the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock worth $756,000 after acquiring an additional 19 shares in the last quarter. Wesbanco Bank Inc. grew its position in shares of Intuitive Surgical by 1.6% during the 4th quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider's stock valued at $635,000 after acquiring an additional 19 shares during the period. Finally, FSM Wealth Advisors LLC raised its holdings in Intuitive Surgical by 3.7% in the 4th quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider's stock worth $275,000 after purchasing an additional 19 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded down $1.36 during trading on Tuesday, hitting $530.46. 1,125,053 shares of the stock traded hands, compared to its average volume of 1,625,419. The stock has a market cap of $190.13 billion, a P/E ratio of 82.76, a PEG ratio of 5.85 and a beta of 1.70. The company has a fifty day moving average price of $503.33 and a two-hundred day moving average price of $534.46. Intuitive Surgical, Inc. has a twelve month low of $379.67 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The company had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the business posted $1.50 earnings per share. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Activity at Intuitive Surgical

In related news, VP Fredrik Widman sold 810 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $573.78, for a total value of $464,761.80. Following the sale, the vice president now directly owns 473 shares in the company, valued at $271,397.94. This trade represents a 63.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director now owns 6,371 shares of the company's stock, valued at $3,312,920. This represents a 27.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,313 shares of company stock valued at $17,229,143 over the last quarter. 0.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on ISRG shares. UBS Group increased their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Barclays decreased their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Citigroup increased their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Erste Group Bank lowered shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 17th. Finally, Royal Bank of Canada cut their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $598.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.